Vitamin D levels and response to biphosphonates in postmenopausal women receiving glucocorticoid therapy

Osteoporosis International

Volumn 25, Issue 8, 2014, Pages 2157-2158

  Ortego Jurado, M ^a   Rios Fernandez R ^a   Callejas Rubio, J L ^a   Gonzalez Gay, M A ^b   Ortego Centeno, N ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; BISPHOSPHONIC ACID DERIVATIVE; PREDNISONE; VITAMIN D;

ADIPOSE TISSUE; BODY MASS; BONE DENSITY; BONE MASS; DRUG HALF LIFE; FEMALE; FEMUR NECK; FOLLOW UP; HUMAN; LETTER; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY OSTEOPOROSIS; VITAMIN SUPPLEMENTATION; WEIGHT GAIN; OSTEOPOROSIS, POSTMENOPAUSAL; VITAMIN D DEFICIENCY;

BONE DENSITY; DIPHOSPHONATES; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84904430399     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2713-6     Document Type: Letter

References (9)

1. Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is >/=33 ng/ml. Osteoporos Int 23:2479-2487
2. Peris P, Martinez-Ferrer A, Monegal A, Martinez de Osaba MJ, Muxi A, Guanabens N (2012) 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone 51:54- 58
3. IshijimaM, Sakamoto Y, YamanakaMet al (2009)Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int 85:398-404
4. Deane A, Constancio L, Fogelman I, Hampson G (2007) The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis. BMC Musculoskelet Disord 8:3
5. Stoch SA, Saag KG, Greenwald M et al (2009) Once-weekly oral alendronate 70mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 36:1705-1714
6. Reid DM, Hughes RA, Laan RF et al (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study J Bone Miner Res 15:1006-1013 (Pubitemid 30350063)
7. Reid DM, Devogelaer JP, Saag K et al (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253-1263
8. Davidson ZE, Walker KZ, Truby H (2012) Clinical review: Do glucocorticosteroids alter vitamin D status? A systematic review with meta-analyses of observational studies. J Clin Endocrinol Metab 97:738-744
9. Holick MF, Binkley NC, Bischoff-Ferrari HA et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911-1930